A Phase 3 interventional study of sacubitril/valsartan in Heart Failure, sponsored by Novartis Pharmaceuticals. Completed at 6 sites in Japan. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing sacubitril in Heart Failure — 5 open to participants now, 5 under way, 2 of them phase 3. sacubitril · Heart Failure.
Among the 24 studies testing sacubitril in Heart Failure, this one is the 20th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 19th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →5 of the 24 studies testing sacubitril in Heart Failure are open now, in 5 countries. Recruiting first, the newest first:
Martin Rohacek · Sites in Tanzania
Ages 18+
Kafrelsheikh University · Sites in Egypt
Ages 18+
John Paul II Hospital, Krakow · Sites in Poland
Ages 18+
Heart Center Research, LLC · Sites in United States
Ages 19+
Puerta de Hierro University Hospital · Sites in Spain
Ages 18+
By country, each count listing its studies:
sacubitril: first FDA approval 2015 (ENTRESTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 104 across the 24 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
74 studies in Heart Failure by Novartis: 4 open now, 4 under way, 2 of them phase 3. Of 68 finished, 38 (56%) have results posted.
Among the 74 studies in Heart Failure by Novartis, this one is the 54th largest by enrollment of the 54 interventional ones that give a count, is one of 5 that started in 2023, is one of 21 in phase 3, and was the 64th registered.
Novartis’s Heart Failure studies by the year they started, since 2002.
1 of the studies testing sacubitril in Heart Failure that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712030Phase 3Puerta de Hierro University HospitalEffect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing sacubitril in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 74 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed CLCZ696B2319E1(NCT03785405) study until marketed product of pediatric formulation, film-coated granules in capsule, is available in Japan.
This trial (CLCZ696B2319E2) was a multicenter, open-label extension study for Japanese patients who have successfully completed the CLCZ696B2319E1 study. Only Japanese patients who successfully completed CLCZ696B2319E1 study and fulfilled protocol requirements were eligible to participate in this study.
The first visit (Visit Day1) was the same day as the End of Study visit of CLCZ696B2319E1 study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The starting dose of study drug was determined by the investigator in consideration of the participant´s condition. The dose level at the end of study visit of CLCZ696B2319E1 study could remain the same, or the dose level could be changed at the discretion of the investigator.
Drug: sacubitril/valsartan
Drug pages: Sacubitril · Valsartan
sacubiril/valsartan
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with treatment emergent adverse events (any AE regardless of seriousness), and SAEs.
Time frame: Adverse events were reported from first dose of study treatment until end of study treatment, up to a maximum duration of approximately 8 months.
Participants took part in 6 investigative sites in Japan.
| Milestone | Sacubitril/Valsartan |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
Number of participants with treatment emergent adverse events (any AE regardless of seriousness), and SAEs.
| Participants | Sacubitril/Valsartan |
|---|---|
| Adverse Events | 6 |
| Serious Adverse Events | 1 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment, up to a maximum duration of approximately 8 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sacubitril/Valsartan | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| All Patients | 0/8 (0%) | 1/8 (12.5%) | 6/8 (75%) |
| Event | Sacubitril/Valsartan | All Patients |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/8 | 1/8 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/8 | 1/8 |
| Event | Sacubitril/Valsartan | All Patients |
|---|---|---|
| NasopharyngitisInfections and infestations | 2/8 | 2/8 |
| VomitingGastrointestinal disorders | 1/8 | 1/8 |
| Seasonal allergyImmune system disorders | 1/8 | 1/8 |
| COVID-19Infections and infestations | 1/8 | 1/8 |
| GastroenteritisInfections and infestations | 1/8 | 1/8 |
| InfluenzaInfections and infestations | 1/8 | 1/8 |
| Otitis mediaInfections and infestations | 1/8 | 1/8 |
| Streptococcal infectionInfections and infestations | 1/8 | 1/8 |
| Upper respiratory tract infectionInfections and infestations | 1/8 | 1/8 |
| Urinary tract infectionInfections and infestations | 1/8 | 1/8 |
| Age, Continuous(years) | Sacubitril/Valsartan |
|---|---|
| Mean | 6.75 ± 4.234 |
| Sex: Female, Male(Participants) | Sacubitril/Valsartan |
|---|---|
| Female | 6 |
| Male | 2 |
| Race/Ethnicity, Customized(Participants) | Sacubitril/Valsartan |
|---|---|
| Asian | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2023 to primary completion in Aug 2024, 8 months.
Results were first posted in Feb 2025, 6 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 8 months is below that.
Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sacubitril · Valsartan